Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Clinical Trials Thursday, September 27th, 2012Practical lessons from ACCORD and other cardiovascular trials
Diabetes Care: October 2012
Four years ago, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was stopped early as the result of increased mortality associated with intensive glycemic treatment of a population with type 2 diabetes (T2DM) and high cardiovascular (CV) risk (1). Further reports have appeared from ACCORD (2) and other studies of high-risk populations, notably the Action in Diabetes and Vascular Disease: Preterax and Diamacron MR Controlled Evaluation (ADVANCE) (3) and the Veterans Affairs Diabetes Trial (VADT) (4). These studies provide a body of evidence that intensive treatment of hyperglycemia in T2DM does not in all cases lead to an acceptable balance of benefits to risks. Although important questions remain, both the main findings and secondary and epidemiological analyses from these studies suggest possible changes of our therapeutic approach. Read More